Diabetes Medications Show Promise in Reducing Dementia and Parkinson's Risks
Recent findings highlight that SGLT2 inhibitors, a class of diabetes medications, may play a critical role in lowering the risk for neurodegenerative diseases such as dementia and Parkinson's disease. This was demonstrated through a study analyzing data from close to 359,000 individuals diagnosed with type 2 diabetes.
The research, published on September 18 in the journal Neurology, indicates that individuals on SGLT2 inhibitors experienced a 20% reduced risk of developing Alzheimer's disease and a 30% lowered risk of dementia linked to vascular issues in the brain.
Dr. Minyoung Lee from Yonsei University College of Medicine in Seoul emphasizes the importance of these findings in a population where diabetes increases the likelihood of cognitive decline. Despite the promising results, further long-term studies are necessary to confirm the lasting protective effects of SGLT2 inhibitors on brain health.
For individuals with diabetes, discussing the option of SGLT2 inhibitors with healthcare providers could potentially lead to improved cognitive health outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.